US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agree

75.33

+0.29000.39%

Volume:332.05K

Turnover:24.99M

Market Cap:8.27B

PE:42.59

High:75.59

Open:75.35

Low:74.71

Close:75.04

Loading ...

Overview Company News Filings

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

FB Financial, Southern States Agree to Merge in $381 Million Stock Deal

MT Newswires Live

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

ADC Therapeutics price target lowered to $7 from $10 at Guggenheim

Carney, Trump Agree to Talks on New U.S.-Canada Deal After Canada's April 28 Vote -- WSJ

ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

LTRN: 2024 Financial Results

Zacks Small Cap Research

Pilot Energy, Triangle Energy Agree to Revised Terms for Cliff Head Oil Joint Venture Deal

MT Newswires Live

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

ADC Therapeutics Says $250.9M In Cash As Of December 31, 2024 Is Expected To Provide Cash Runway Into The Second Half Of 2026

ADC Therapeutics Q4 2024 Adj EPS $(0.25) Beats $(0.41) Estimate, Sales $16.91M Miss $19.01M Estimate

Press Release: PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation

MT Newswires Live

Press Release: Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Realty Income Stock Offers High Dividend Yield: Buy, Hold or Sell?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ADC/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"Agree","latestPrice":75.33,"timestamp":1748366147080,"preClose":75.04,"halted":0,"volume":332046,"delay":0,"floatShares":107727624,"shares":109806548,"eps":1.768583,"marketStatus":"Trading","change":0.29,"latestTime":"05-27 13:15:47 EDT","open":75.345,"high":75.59,"low":74.71,"amount":24986023.199279997,"amplitude":0.011727,"askPrice":75.33,"askSize":308,"bidPrice":75.29,"bidSize":29,"shortable":3,"etf":0,"ttmEps":1.768583,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1748376000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":75.04,"dividendRate":0.040064,"preHourTrading":{"tag":"盘前","latestPrice":75.6,"preClose":75.04,"latestTime":"09:27 EDT","volume":98,"amount":7409.5007000000005,"timestamp":1748352441764},"postHourTrading":{"tag":"盘后","latestPrice":75.33,"preClose":75.04,"latestTime":"16:34 EDT","volume":13110,"amount":983828.62,"timestamp":1748032465719},"volumeRatio":0.557811,"impliedVol":0.2403,"impliedVolPercentile":0.744},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADC\",,,,,undefined,":{"symbol":"ADC","floatShares":107727624,"roa":"2.30%","roe":"3.55%","lyrEps":1.793039,"volumeRatio":0.557811,"shares":109806548,"dividePrice":3.018,"high":75.59,"amplitude":0.011727,"preClose":75.04,"low":74.71,"week52Low":58.52,"pbRate":"1.51","psRate":"12.99","week52High":79.65,"institutionHeld":0.8991,"latestPrice":75.33,"committee":-0.827893,"eps":1.768583,"divideRate":0.040064,"volume":332046,"delay":0,"ttmEps":1.768583,"open":75.345,"prevYearClose":70.45,"prevWeekClose":75.04,"prevMonthClose":77.61,"prevQuarterClose":77.19,"fiveDayClose":75.7,"twentyDayClose":76.43,"sixtyDayClose":73.8},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADC\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523092138","title":"TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523092138","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523092138?lang=en_us&edition=fundamental","pubTime":"2025-03-31 23:20","pubTimestamp":1743434400,"startTime":"0","endTime":"0","summary":"Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or af","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052498/0/en/TIVDAK-tisotumab-vedotin-Approved-by-European-Commission-for-Previously-Treated-Recurrent-or-Metastatic-Cervical-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU1066051498.USD","BK4581","IE000M9KFDE8.USD","BK4599","L","IE0002270589.USD","SG9999002224.SGD","LU0225284248.USD","LU0058720904.USD","SG9999011175.SGD","LU0985481810.HKD","SG9999013999.USD","LU0170899867.USD","LU1883839398.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU0321505439.SGD","LU0053666078.USD","BK4585","BK4007","BK4534","IE00B19Z3581.USD","IE00B19Z3B42.SGD","EC","MAA","SG9999001176.USD","OS","BK4080","LU0321505868.SGD","BK4231","BK4592","LU1057294990.SGD","BK4533","ADC","BK4107","BK4201","PFS","SG9999003800.SGD","ORR","BK4097","IE00BBT3K403.USD","LU0306806265.USD","BK4550","LU0234572021.USD","LU1894683264.USD","LU0122379950.USD","LU0868494617.USD"],"gpt_icon":1},{"id":"2523294571","title":"FB Financial, Southern States Agree to Merge in $381 Million Stock Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2523294571","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523294571?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:11","pubTimestamp":1743423089,"startTime":"0","endTime":"0","summary":"FB Financial  and Southern States Bancshares  said Monday they have agreed to merge in a stock-based transaction valued at roughly $381 million.Southern States investors will receive 0.8 shares of FB Financial for each of their existing shares, translating to about $37.64 per share, according to a joint statement.The merger will expand FB Financial's presence in Alabama and Georgia, adding 15 branches and two loan offices, the companies said.The deal is expected to close in late Q3 or early Q4, pending shareholder and regulatory clearance, the companies added.Shares of Southern States were up over 9%, while FB Financial stock was off 0.3% in recent premarket activity Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BMG7P694.USD","SO","LU1621767810.EUR","BK4588","LU1621768115.EUR","LU0211328371.USD","LU1621767737.EUR","IE00B29SXL02.USD","LU1267930490.SGD","FBK","LU1621768206.USD","BK4211","LU0211327993.USD","LU2133065610.SGD","BK4081","BK4585","BK4231","IE00BMG7P587.USD","SSBK","IE00B29SXK94.USD","LU1162221912.USD","IE00BMG7P926.USD","LU1929549753.HKD","IE00BMG7P819.SGD","ADC","LU2384288077.EUR","BK4080","BK4539","LU1718418525.SGD","LU0320765646.SGD","LU0310799852.SGD"],"gpt_icon":0},{"id":"2523958946","title":"DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523958946","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523958946?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., March 31, 2025----The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU  in combination with a fluoropyrimidine chemotherapy  and Merck’s  anti-PD-1 therapy KEYTRUDA  versus trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive  gastric or gastroesophageal junction  cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy.Gastric cancer is associated with a poor prognosis, particularly in advanced stages of the disease where the five-year survival rate is 5% to 10%.1 Current recommended first-line treatment for HER2 positive advanced gastric cancer with PD-L1 CPS ≥1 is trastuzumab in combination with platinum-based chemotherapy  and pembrolizumab.2,3 New treatment strategies ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/destiny-gastric05-phase-3-trial-120000580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4225","BK4195","BK4080","IE00B19Z4B17.USD","DSKYF","BK4231","BK4007","PBD","IE0031619046.USD","BK4211","IE00B7SZL793.SGD","BK4157","DSNKY","AEIS","IE00B66KJ199.SGD","BK4203","ADC","HR","PFS"],"gpt_icon":0},{"id":"2523456169","title":"OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2523456169","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523456169?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:40","pubTimestamp":1743421200,"startTime":"0","endTime":"0","summary":"New canine elite responder biomarkers added to human biomarker strategy. NEW YORK, March 31, 2025----OS Therapies  , a clinical-stage immunotherapy and Antibody Drug Conjugate  biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria monocytogenes  immunotherapeutic cancer biologic drug candidate in the prevention or delay of fully-resected, recurrent, lung metastatic osteosarcoma.\"We are making rapid progress in putting together an appropriate data package to achieve accelerated approval for OST-HER2 given the feedback we’ve received to date from the FDA,\" said Paul Romness, MHP, Chairman & CEO of OS Therapies. \"We know one of the US government’s stated priorities is to treat deadly childhood cancers, and we believe that OST-HER2 for osteosarcoma aligns well with that mission.\". The Company initiated regulatory correspondence with the US Food & Drug Administration  and the United Kingdom’s Medicines and Healthcare products Regulatory Agency  in the first","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/os-therapies-provides-regulatory-rare-114000177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OSTX","NICE","BK4139","BK4080","BK4097","OST","BK4566","IE00BFMHRM44.USD","BK4148","OS","BK4017","BK4023","ADC","BK4543","DC","BK4231"],"gpt_icon":0},{"id":"2523917917","title":"ADC Therapeutics price target lowered to $7 from $10 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2523917917","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523917917?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418841,"startTime":"0","endTime":"0","summary":"Guggenheim lowered the firm’s price target on ADC Therapeutics (ADCT) to $7 from $10 and keeps a Buy rating on the shares. Q4 results were largely ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-price-target-lowered-to-7-from-10-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-price-target-lowered-to-7-from-10-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADC","LENZ"],"gpt_icon":0},{"id":"2523878685","title":"Carney, Trump Agree to Talks on New U.S.-Canada Deal After Canada's April 28 Vote -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2523878685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523878685?lang=en_us&edition=fundamental","pubTime":"2025-03-29 01:15","pubTimestamp":1743182100,"startTime":"0","endTime":"0","summary":"Canadian Prime Minister Mark Carney says he and President Trump agreed that negotiations on a new economic and security partnership between the two countries should begin immediately after Canada's April 28 election.In the meantime, Carney warned Trump his government would impose retaliatory tariffs on U.S. goods following the planned reveal on April 2 of new U.S. duties on a range of global imports--among them, Canadian-made vehicles and auto parts.Canada's Prime Minister's Office released a summary of the call between the two leaders, about 90 minutes after Trump said in a TruthSocial post that the two men had an \"extremely productive\" conversation. The summary also indicated that talks between Canadian Finance Minister Dominic LeBlanc and Commerce Secretary Howard Lutnick would \"intensify to address immediate concerns.\". Carney is seeking a mandate from voters in an election set for April 28, and polls indicate that either the Liberals hold a lead or are in a tight race with the Con","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"2522520091","title":"ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2522520091","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522520091?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:11","pubTimestamp":1743160284,"startTime":"0","endTime":"0","summary":"We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NYSE:ADCT Earnings and Revenue Growth March 28th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 2.7%. Earnings per share  exceeded analyst estimates by 4.1%.Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are down 11% from a week ago.It's necessary to consider the ever-present spectre of investment risk.   We've identified 4 warning signs  with ADC Therapeutics , and understanding these should be part of your investment process.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-full-2024-earnings-111124252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADCT","LENZ","ADC"],"gpt_icon":0},{"id":"2522501367","title":"LTRN: 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522501367","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522501367?lang=en_us&edition=fundamental","pubTime":"2025-03-28 18:20","pubTimestamp":1743157200,"startTime":"0","endTime":"0","summary":"Lantern Pharma, Inc  reports 2024 results highlighting several achievements including progress on its HARMONIC, LP-184 and LP-284 trials, a portfolio of expedited designations in multiple indications and advances in the RADR platform with modules that offer predictive algorithms for blood brain barrier  penetration and antibody drug conjugate  design.On March 27th, 2025, Lantern announced 2024 financial and operational results, filed its Form 10-K with the SEC and hosted a video webcast to review accomplishments. A slide deck was included to guide the discussion. In the financial sphere, Lantern generated no revenues in 2024 and incurred operating expense of $22.2 million, producing a net loss of  million or  per share.General & administrative expenses were $6.1 million, rising 2% from $6.0 million. Higher professional fees were partially offset by lower wage and benefit costs, a decrease in insurance expense and a decline in stock","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ltrn-2024-financial-results-102000980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","LU0889565916.HKD","USAW.SI","ADC","PSQ","TSYW.SI","JAZZ","IE00BN0W2T93.GBP","BK4007","MNQmain","TQQQ","USJW.SI","NQmain","BK4231","QID","BK4583","LTRN","LU0823416689.USD","BK4139","LU0109394709.USD","QLD","CMRX","BK4532","SQQQ","BK4533","IE00BN0W2W23.USD","NVIW.SI","IE00BN0W2V16.EUR",".IXIC","BK4080"],"gpt_icon":1},{"id":"2522135715","title":"Pilot Energy, Triangle Energy Agree to Revised Terms for Cliff Head Oil Joint Venture Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2522135715","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522135715?lang=en_us&edition=fundamental","pubTime":"2025-03-28 14:17","pubTimestamp":1743142672,"startTime":"0","endTime":"0","summary":"Pilot Energy  agreed revised terms with Triangle Energy   to acquire 100% of the interests in the Cliff Head oil joint venture and assets, according to a Friday Australian bourse filing.Under the revised terms, Pilot will purchase the Western Australia-based assets of the joint venture through a vendor financing arrangement, which will see Pilot providing a secured note to Triangle worth AU$5.6 million.The note will have a maturity date of Sept. 30, 2026, or earlier in the event of a sale of a material interest in the joint venture by Pilot to a third party. The note will accrue interest from June 30 at 10% which will be capitalized to maturity.Pilot will also make a one-off cash payment to Triangle of AU$167,000 on August 31 in recognition of the deferred interest accrual under the note.Subject to approval from the National Offshore Petroleum Titles Administrator, the transfer of the remaining joint venture assets and licenses located in waters offshore Australia, to Pilot will be com","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JYNT","PGY.AU","TEG.AU","XKO.AU","XJO.AU","BK4185","BK4231","BK7142","BK4080","XAO.AU","ADC"],"gpt_icon":0},{"id":"2522533947","title":"Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2522533947","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522533947?lang=en_us&edition=fundamental","pubTime":"2025-03-28 02:27","pubTimestamp":1743100046,"startTime":"0","endTime":"0","summary":"The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ Tivdak  for advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy.Tivdak is the first and only antibody-drug conjugate  to be approved for cervical cancer in Japan.The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced or recurrent cervical cancer who were previously treated with chemotherapy.Also Read: AbbVie/Genmab’s Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway. The trial included 502 patients, 101 of which were Japanese.Median OS was 11.5 months among patients treated with Tivdak compared to 9.5 months for patients who received chemotherapy. Secondary endpoints of progression-free survival  and confirmed objective response rate  were also met.This article Japanese Drug Regulator Approves Genmab","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/japanese-drug-regulator-approves-genmab-182726829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","LU0225284248.USD","LU1057294990.SGD","BK4568","LU0306807586.USD","IE00BLSP4239.USD","GMAB","IE00B19Z4B17.USD","IE00BLSP4452.SGD","LU0985481810.HKD","LU0058720904.USD","LU0170899867.USD","ORR","BK4585","OS","BK4139","LU1066053197.SGD","BK4007","SG9999001176.SGD","LU0234572021.USD","BK4599","LU1894683264.USD","IE0031619046.USD","LU0321505439.SGD","LU0321505868.SGD","LU0122379950.USD","BK4211","IE00B7SZL793.SGD","BK4534","BK4550","LU1883839398.USD","LU0456855351.SGD","BK4592","IE0002270589.USD","IE00B19Z3581.USD","BK4157","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","BK4533","AEIS","IE00B66KJ199.SGD","LU0289739699.SGD","BK4588","ADC","SG9999001176.USD","LU1066051498.USD","PFS","IE00BBT3K403.USD","SG9999013999.USD"],"gpt_icon":1},{"id":"2522049307","title":"ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522049307","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522049307?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:35","pubTimestamp":1743078902,"startTime":"0","endTime":"0","summary":"ADC Therapeutics SA  came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.14%. A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.42, delivering a surprise of -16.67%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.ADC Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $16.91 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 14.01%. This compares to year-ago revenues of $16.79 million. The company has not been able to beat consensus revenue estimates over the last four quarters.Investors should be mindful of the fact that the outlook for the industry can have a material im","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-sa-adct-reports-123502890.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","ADCT"],"gpt_icon":0},{"id":"2522305374","title":"TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522305374","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522305374?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:00","pubTimestamp":1743076800,"startTime":"0","endTime":"0","summary":"TIVDAK is the first and only antibody-drug conjugate  approved for patients with advanced or recurrent cervical cancer in Japan. Approval is based on results from the global Phase 3 innovaTV 301 trial, in which TIVDAK demonstrated superior overall survival compared to chemotherapy. Rising cervical cancer incidence and mortality rates in Japan signify need for new treatment options. COPENHAGEN, Denmark, March 27, 2025----Genmab A/S  today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK  for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan.In recent years, cervical cancer incidence and mortality rates have increased in Japan, particularly among women under age 50.i,ii,iii Moreover, patients with recurrent or metastatic cervical cancer whose disease has progressed after first-line therapy have limited","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tivdak-tisotumab-vedotin-approved-japan-120000054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0456855351.SGD","IE0002270589.USD","LU1894683348.USD","ADC","SGXZ57979304.SGD","LU1057294990.SGD","GMAB","IE00B19Z3581.USD","IE00B19Z4B17.USD","SG9999013999.USD","BK4550","LU0289739699.SGD","OS","LU0321505439.SGD","BK4139","PFS","L","AEIS","LU0306807586.USD","SG9999002232.USD","SG9999003800.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4080","LU0225284248.USD","ORR","BK4599","BK4007","PN","BK4107","IE0031619046.USD","LU0122379950.USD","SG9999011175.SGD","LU0170899867.USD","LU0058720904.USD","BK4585","LU0321505868.SGD","BK4533","SG9999001176.SGD","BK4592","LU0053666078.USD","BK4157","LU1066051498.USD","LU1883839398.USD","SG9999002224.SGD","BK4097","LU0868494617.USD","LU1066053197.SGD","BK4568"],"gpt_icon":1},{"id":"2522374205","title":"Press Release: CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374205?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:55","pubTimestamp":1743076500,"startTime":"0","endTime":"0","summary":"-      Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.-          EU & UK: Approved for first-line treatment of stage IV non-small cell lung cancer ; stage III NSCLC new indication application submitted to EMA.-     Global Partnerships: Three strategic partnerships across 40+ countries, to accelerate global commercialization.-      Localized Production: Approved for localized manufacturing in China, enhancing cost efficiency.-      Commercial Collaboration: Partnered with Hengrui to expand market access in China.-      Leading Position: Top 2 globally in clinical development for ROR1-targeted ADCs.-      Preclinical Differentiation: Superior tumor suppression vs. benchmarked competitors; potential first-in-class/best-in-class IO backbone therapy.-      More than 9 Differentiated Candidates: Focus on first-in-class/best-in-class assets, including multispecific antibodies and ADCs, with global rights and broad therapeutic potential.SUZHOU, Ch","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","OS","LU2249611893.SGD","CEE","BK4585","LU2357125470.USD","ORR","R","LU0823414478.USD","ASH","BK4570","BK4210","BK4195","BK4017","BK4182","BK4232","PFS","BK4097","LU0444973449.USD","PRGS","BK4124","BK4211","ADC","LU2294711713.HKD","LU0345780521.USD","LU0444971666.USD","HL","BK4022","BK4588","BK1574","LU0476273544.USD","CPS","LU0823414551.USD","BK4213","LU2506951792.HKD","LU2463526074.USD","BK1161","LU2065732104.USD","LU0957808578.USD","BE","BK4541","LU1642822529.SGD","CDE","SITC","BK4080","LU1815336760.USD","02616","SOC","BK4109"],"gpt_icon":0},{"id":"2522892371","title":"ADC Therapeutics Says $250.9M In Cash As Of December 31, 2024 Is Expected To Provide Cash Runway Into The Second Half Of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2522892371","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522892371?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:35","pubTimestamp":1743075322,"startTime":"0","endTime":"0","summary":"ADC Therapeutics Says $250.9M In Cash As Of December 31, 2024 Is Expected To Provide Cash Runway Into The Second Half Of 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44511431/adc-therapeutics-says-250-9m-in-cash-as-of-december-31-2024-is-expected-to-provide-cash-runway-into","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4080","BK4231","LENZ","BK4139","ADC","ADCT"],"gpt_icon":0},{"id":"2522718643","title":"ADC Therapeutics Q4 2024 Adj EPS $(0.25) Beats $(0.41) Estimate, Sales $16.91M Miss $19.01M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522718643","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522718643?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:34","pubTimestamp":1743075250,"startTime":"0","endTime":"0","summary":"ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.41) by 39.02 percent. This is a 74.23 percent increase over losses of $(0.97) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44511429/adc-therapeutics-q4-2024-adj-eps-0-25-beats-0-41-estimate-sales-16-91m-miss-19-01m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADCT","ADC","LENZ"],"gpt_icon":0},{"id":"2522792723","title":"Press Release: PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522792723","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522792723?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:30","pubTimestamp":1743075000,"startTime":"0","endTime":"0","summary":"Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer. Conference call and webcast today at 8:00 a.m. Eastern Time. PRINCETON, N.J., March 27, 2025  -- PDS Biotechnology Corporation  , a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a clinical programs update and reported financial results for the full year ended December 31, 2024.-- Phase 3 VERSATILE-003 Trial in HPV16-positive first-line recurrent and/or. -- Announced activation of the first site in March 2025. -- Trial designed to include approximately 350 patients. -- PDS Biotech is aligned with the U.S. Food and Drug Administration.  on the design of the registrational trial and clinical. -- Design based on strong and durable responses seen in the. -- The Company received Fast Track designation from the FDA for the. combination of Versamune HPV and pembrolizumab in R/M HNSCC.-- For more information on","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4092","BK4604","BK4555","TM","BK4139","BK4232","R","03160","BK4080","BK4099","BK4588","PDS","BK4585","PDSB","ADC","BK4022","BK4231"],"gpt_icon":0},{"id":"2522379277","title":"Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522379277","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522379277?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:30","pubTimestamp":1743075000,"startTime":"0","endTime":"0","summary":"ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update. Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025. Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached. $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026. LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.Fourth Quarter 2024 Operational Updates and Upcoming Milestones. and the complete response rate  was 72%. Th","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","BK4211","BK4231","TM","BK4604","PBD","LU2463526074.USD","BK4080","BK4109","ORR","PFS","BK4094","BK4099","BK4139","BK4232","BK4555","ADCT","ADC","ASH","03160","BK4505","LENZ","BK4585","BK4195","BK4022","FL"],"gpt_icon":0},{"id":"2522134338","title":"Shandong Boan Biotechnology Cancer Drug Granted U.S. FDA Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2522134338","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522134338?lang=en_us&edition=fundamental","pubTime":"2025-03-27 15:44","pubTimestamp":1743061459,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology  said its novel CD228-directed antibody-drug conjugate , BA1302, received Orphan Drug Designation  from the Food and Drug Administration  for the treatment of squamous non-small cell lung cancer  and pancreatic cancer, according to a Wednesday filing with the Hong Kong bourse.BA1302 targets CD228, a protein overexpressed in multiple tumors, to inhibit cancer cell migration and proliferation while minimizing off-target toxicity.The biopharmaceutical company's shares were up 2% in recent trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK4183","06955","BK7095","ODD","BK4231","ADC.AU","BK4080","ADC"],"gpt_icon":0},{"id":"2522304123","title":"Press Release: Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304123","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304123?lang=en_us&edition=fundamental","pubTime":"2025-03-27 04:05","pubTimestamp":1743019500,"startTime":"0","endTime":"0","summary":"Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer . Topline data from registration-intent DENALI Part 2 anticipated by year end 2026. Strengthened management team to support execution of highly focused strategy. $371.1 million cash, cash equivalents and marketable securities balance as of December 31, 2024, with projected cash runway into late 2027. \"Zentalis reported significant progress in the development of azenosertib in 2024 and made important advancements this year. We plan to maintain strong execution on the late-stage development of azenosertib,\" said Julie Eastland, Chief Executive Officer of Zentalis. \"The clinical data we recently presented supports rapid advancement of azenosertib as a monotherapy therapy for patients with Cyclin E1+ PROC, and the continued development of azenosertib in other settings of ovarian cancer and other tumor types. With a sharpened focus on clinical developme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4231","ZNTL","PROC","BK4139","BK4022","ADC","BK4232","ORR","BK4080","R"],"gpt_icon":1},{"id":"2522564293","title":"Realty Income Stock Offers High Dividend Yield: Buy, Hold or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522564293","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522564293?lang=en_us&edition=fundamental","pubTime":"2025-03-27 03:00","pubTimestamp":1743015600,"startTime":"0","endTime":"0","summary":"Is Realty Income's Growth and Dividend Built to Last?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/realty-income-stock-offers-high-190000674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["US5Y.BOND","US6M.BOND","BK4080","US2Y.BOND","BK4529","BK4566","DLR","ADC","BK4231","BK4084","US30Y.BOND","O","BK4588","US12M.BOND","BK4585","US3Y.BOND","BK4222","US10Y.BOND","US7Y.BOND"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADC\",params:#limit:5,,,undefined,":[{"date":"2025-05-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-30","defaultRemindTime":1748611800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-13","payableDate":"2025-05-30","currency":"USD","dateTimestamp":1748577600000,"payDate":"2025-06-13"},{"date":"2025-04-30","symbol":"ADC","amount":0.256,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-30","defaultRemindTime":1746019800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-14","payableDate":"2025-04-30","currency":"USD","dateTimestamp":1745985600000,"payDate":"2025-05-14"},{"market":"US","date":"2025-04-22","symbol":"ADC","fiscalQuarterEnding":"2025/03","expectedEps":1.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745294400000,"reportTimeType":"post","actualEps":1.06},{"date":"2025-03-31","symbol":"ADC","amount":0.253,"announcedDate":"2025-03-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-31","defaultRemindTime":1743427800000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-14","payableDate":"2025-03-31","currency":"USD","dateTimestamp":1743393600000,"payDate":"2025-04-14"},{"date":"2025-02-28","symbol":"ADC","amount":0.253,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-28","defaultRemindTime":1740753000000,"name":"艾格里房产","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-14","payableDate":"2025-02-28","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADC\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-26","recordDate":"2015-06-30","paymentDate":"2015-07-14","value":0.465,"currency":"USD"},{"executeDate":"2015-09-28","recordDate":"2015-09-30","paymentDate":"2015-10-13","value":0.465,"currency":"USD"},{"executeDate":"2015-12-18","recordDate":"2015-12-22","paymentDate":"2016-01-05","value":0.465,"currency":"USD"},{"executeDate":"2016-03-29","recordDate":"2016-03-31","paymentDate":"2016-04-15","value":0.465,"currency":"USD"},{"executeDate":"2016-06-28","recordDate":"2016-06-30","paymentDate":"2016-07-15","value":0.48,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2857,"buy":0.4286,"hold":0.2857,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4286,"analysts":21,"updateTime":1746849600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADC","date":"2025-05-23","current":42.755537,"percent":0.651749,"low":31.539495,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"high":53.261716,"avg":41.115349,"sd":4.473929,"marketCap":8180587826},"quantilePoints":[{"date":"2020-05-29","current":40.87144,"twenty":30.127131,"median":35.446997,"eighty":42.650816,"marketCap":3390817259},{"date":"2020-06-05","current":44.67404,"twenty":30.209273,"median":35.585113,"eighty":42.788104,"marketCap":3706292371},{"date":"2020-06-12","current":43.306667,"twenty":30.259415,"median":35.631973,"eighty":42.882133,"marketCap":3592850978},{"date":"2020-06-19","current":43.938263,"twenty":30.399208,"median":35.674606,"eighty":42.926676,"marketCap":3645250098},{"date":"2020-06-26","current":40.969109,"twenty":30.470777,"median":35.744304,"eighty":42.989446,"marketCap":3398920216},{"date":"2020-07-02","current":43.619209,"twenty":30.497525,"median":35.833506,"eighty":43.024146,"marketCap":3618780439},{"date":"2020-07-10","current":41.587683,"twenty":30.543737,"median":35.93098,"eighty":43.037844,"marketCap":3450238941},{"date":"2020-07-17","current":42.77274,"twenty":30.603622,"median":36.099734,"eighty":43.037844,"marketCap":3548554815},{"date":"2020-07-24","current":37.537078,"twenty":30.71291,"median":36.149452,"eighty":43.037844,"marketCap":3365424257},{"date":"2020-07-31","current":40.350852,"twenty":30.745133,"median":36.199495,"eighty":43.037844,"marketCap":3617696027},{"date":"2020-08-07","current":41.351038,"twenty":30.776927,"median":36.250246,"eighty":43.037844,"marketCap":3707368648},{"date":"2020-08-14","current":40.224323,"twenty":30.922362,"median":36.348523,"eighty":43.037844,"marketCap":3606351900},{"date":"2020-08-21","current":40.308676,"twenty":31.08368,"median":36.544296,"eighty":43.037844,"marketCap":3613914651},{"date":"2020-08-28","current":40.628012,"twenty":31.203975,"median":36.640352,"eighty":43.037844,"marketCap":3642545066},{"date":"2020-09-04","current":40.013441,"twenty":31.296906,"median":36.781594,"eighty":43.037844,"marketCap":3587445022},{"date":"2020-09-11","current":40.079718,"twenty":31.383772,"median":36.974643,"eighty":43.037844,"marketCap":3593387184},{"date":"2020-09-18","current":38.59149,"twenty":31.509762,"median":37.052903,"eighty":43.037844,"marketCap":3459958646},{"date":"2020-09-25","current":37.645532,"twenty":31.534039,"median":37.273263,"eighty":43.037844,"marketCap":3375147794},{"date":"2020-10-02","current":39.29644,"twenty":31.704694,"median":37.362034,"eighty":43.037844,"marketCap":3523161638},{"date":"2020-10-09","current":40.368928,"twenty":31.803276,"median":37.497873,"eighty":43.037844,"marketCap":3619316617},{"date":"2020-10-16","current":39.386818,"twenty":31.867808,"median":37.57347,"eighty":43.037844,"marketCap":3531264585},{"date":"2020-10-23","current":40.224079,"twenty":31.975443,"median":37.612137,"eighty":43.037844,"marketCap":3633239960},{"date":"2020-10-30","current":38.164301,"twenty":31.975443,"median":37.733323,"eighty":43.037844,"marketCap":3447190528},{"date":"2020-11-06","current":38.797606,"twenty":31.975443,"median":37.935059,"eighty":43.037844,"marketCap":3504393786},{"date":"2020-11-13","current":41.26934,"twenty":31.975443,"median":38.046028,"eighty":43.037844,"marketCap":3727653105},{"date":"2020-11-20","current":40.039622,"twenty":31.975443,"median":38.167733,"eighty":43.037844,"marketCap":3616578817},{"date":"2020-11-27","current":40.506914,"twenty":31.975443,"median":38.310136,"eighty":43.037844,"marketCap":3658787046},{"date":"2020-12-04","current":40.580698,"twenty":31.975443,"median":38.471704,"eighty":43.037844,"marketCap":3665451504},{"date":"2020-12-11","current":40.230228,"twenty":31.975443,"median":38.545534,"eighty":43.037844,"marketCap":3633795331},{"date":"2020-12-18","current":39.344831,"twenty":31.975443,"median":38.676992,"eighty":43.037844,"marketCap":3553821844},{"date":"2020-12-24","current":39.762935,"twenty":31.975443,"median":38.782235,"eighty":43.037844,"marketCap":3591587102},{"date":"2020-12-31","current":40.937316,"twenty":31.975443,"median":38.892751,"eighty":43.037844,"marketCap":3697663047},{"date":"2021-01-08","current":45.450661,"twenty":31.975443,"median":39.008592,"eighty":43.047885,"marketCap":4105330986},{"date":"2021-01-15","current":44.653159,"twenty":31.975443,"median":39.245492,"eighty":43.22631,"marketCap":4033296550},{"date":"2021-01-22","current":45.359718,"twenty":31.975443,"median":39.341757,"eighty":43.313411,"marketCap":4097116533},{"date":"2021-01-29","current":44.212433,"twenty":31.975443,"median":39.41667,"eighty":43.4163,"marketCap":3993488046},{"date":"2021-02-05","current":46.262155,"twenty":31.975443,"median":39.41667,"eighty":43.554978,"marketCap":4178629185},{"date":"2021-02-12","current":45.520618,"twenty":31.975443,"median":39.41667,"eighty":43.618647,"marketCap":4111649797},{"date":"2021-02-19","current":43.859591,"twenty":31.975443,"median":39.41667,"eighty":43.642628,"marketCap":4007933303},{"date":"2021-02-26","current":44.718497,"twenty":31.977009,"median":39.430911,"eighty":43.756513,"marketCap":4086420942},{"date":"2021-03-05","current":44.656157,"twenty":31.975443,"median":39.41667,"eighty":43.796506,"marketCap":4080724259},{"date":"2021-03-12","current":46.594043,"twenty":31.975443,"median":39.41667,"eighty":43.856021,"marketCap":4257810284},{"date":"2021-03-19","current":46.240217,"twenty":31.975443,"median":39.41667,"eighty":43.889974,"marketCap":4225477299},{"date":"2021-03-26","current":46.69811,"twenty":31.977009,"median":39.430911,"eighty":43.995818,"marketCap":4267319985},{"date":"2021-04-01","current":47.239256,"twenty":31.977009,"median":39.430911,"eighty":44.083322,"marketCap":4316770432},{"date":"2021-04-09","current":47.1005,"twenty":31.975443,"median":39.41667,"eighty":44.146464,"marketCap":4304090831},{"date":"2021-04-16","current":47.627771,"twenty":31.975443,"median":39.41667,"eighty":44.201737,"marketCap":4352273317},{"date":"2021-04-23","current":49.334461,"twenty":31.975443,"median":39.41667,"eighty":44.216631,"marketCap":4508232419},{"date":"2021-04-30","current":48.814129,"twenty":31.975443,"median":39.41667,"eighty":44.274005,"marketCap":4460683913},{"date":"2021-05-07","current":44.881383,"twenty":31.975443,"median":39.41667,"eighty":44.314742,"marketCap":4499986938},{"date":"2021-05-14","current":44.377456,"twenty":31.975443,"median":39.41667,"eighty":44.249425,"marketCap":4449461218},{"date":"2021-05-21","current":44.026621,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4414285084},{"date":"2021-05-28","current":44.830352,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4494870410},{"date":"2021-06-04","current":45.665977,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4578653566},{"date":"2021-06-11","current":45.646841,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4576734868},{"date":"2021-06-18","current":47.246871,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4737160278},{"date":"2021-06-25","current":48.748389,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4887708512},{"date":"2021-07-02","current":48.211648,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4833892628},{"date":"2021-07-09","current":49.210395,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":4934031046},{"date":"2021-07-16","current":49.93058,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5006239701},{"date":"2021-07-23","current":50.956505,"twenty":31.977009,"median":39.430911,"eighty":44.196388,"marketCap":5109102975},{"date":"2021-07-30","current":53.056971,"twenty":31.977009,"median":39.430911,"eighty":44.230599,"marketCap":5165308396},{"date":"2021-08-06","current":52.598062,"twenty":31.977009,"median":39.430911,"eighty":44.296692,"marketCap":5120631744},{"date":"2021-08-13","current":52.520401,"twenty":31.977009,"median":39.430911,"eighty":44.412506,"marketCap":5113071079},{"date":"2021-08-20","current":52.718085,"twenty":31.977009,"median":39.430911,"eighty":44.625208,"marketCap":5132316407},{"date":"2021-08-27","current":52.209754,"twenty":31.977009,"median":39.430911,"eighty":44.658936,"marketCap":5082828422},{"date":"2021-09-03","current":52.675724,"twenty":31.977009,"median":39.430911,"eighty":44.712504,"marketCap":5128192408},{"date":"2021-09-10","current":49.555141,"twenty":31.977009,"median":39.430911,"eighty":44.74795,"marketCap":4824391169},{"date":"2021-09-17","current":50.119952,"twenty":31.977009,"median":39.430911,"eighty":44.835833,"marketCap":4879377818},{"date":"2021-09-24","current":47.775985,"twenty":31.977009,"median":39.430911,"eighty":44.888065,"marketCap":4651183223},{"date":"2021-10-01","current":47.352376,"twenty":31.977009,"median":39.430911,"eighty":44.941549,"marketCap":4609943235},{"date":"2021-10-08","current":47.670083,"twenty":31.977009,"median":39.430911,"eighty":44.9864,"marketCap":4640873226},{"date":"2021-10-15","current":49.02563,"twenty":31.977009,"median":39.430911,"eighty":45.094688,"marketCap":4772841185},{"date":"2021-10-22","current":49.5269,"twenty":31.977009,"median":39.430911,"eighty":45.190701,"marketCap":4821641836},{"date":"2021-10-29","current":50.169373,"twenty":32.013133,"median":39.571166,"eighty":45.28245,"marketCap":4884189150},{"date":"2021-11-05","current":43.773853,"twenty":32.013133,"median":39.651928,"eighty":45.28245,"marketCap":4934976633},{"date":"2021-11-12","current":43.137928,"twenty":32.029424,"median":39.72736,"eighty":45.28245,"marketCap":4863283742},{"date":"2021-11-19","current":43.008274,"twenty":32.198132,"median":39.802558,"eighty":45.28245,"marketCap":4848666745},{"date":"2021-11-26","current":42.662528,"twenty":32.27459,"median":39.842867,"eighty":45.28245,"marketCap":4809688086},{"date":"2021-12-03","current":42.508177,"twenty":32.348817,"median":39.911012,"eighty":45.28245,"marketCap":4792286899},{"date":"2021-12-10","current":42.891493,"twenty":32.447032,"median":39.953188,"eighty":45.28245,"marketCap":4835501148},{"date":"2021-12-17","current":45.380751,"twenty":32.521786,"median":39.996581,"eighty":45.380751,"marketCap":5116135105},{"date":"2021-12-23","current":46.352906,"twenty":32.588031,"median":40.079057,"eighty":45.406143,"marketCap":5225733953},{"date":"2021-12-31","current":48.175698,"twenty":32.64443,"median":40.10618,"eighty":45.47788,"marketCap":5431231792},{"date":"2022-01-07","current":46.703962,"twenty":32.651599,"median":40.164071,"eighty":45.565296,"marketCap":5265311314},{"date":"2022-01-14","current":46.015352,"twenty":32.70478,"median":40.208708,"eighty":45.667046,"marketCap":5187678797},{"date":"2022-01-21","current":43.267663,"twenty":32.731462,"median":40.224323,"eighty":45.667046,"marketCap":4877909831},{"date":"2022-01-28","current":43.821252,"twenty":32.743358,"median":40.249944,"eighty":45.667046,"marketCap":4940320287},{"date":"2022-02-04","current":42.666817,"twenty":32.769192,"median":40.314701,"eighty":45.667046,"marketCap":4810171655},{"date":"2022-02-11","current":42.565551,"twenty":32.769192,"median":40.347561,"eighty":45.667046,"marketCap":4798755108},{"date":"2022-02-18","current":42.943612,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4841376882},{"date":"2022-02-25","current":37.784604,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4620036905},{"date":"2022-03-04","current":38.267307,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4679058463},{"date":"2022-03-11","current":37.29027,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4559593141},{"date":"2022-03-18","current":37.24956,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4554615419},{"date":"2022-03-25","current":38.110019,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4659826391},{"date":"2022-04-01","current":39.298046,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4805089927},{"date":"2022-04-08","current":39.763938,"twenty":32.769192,"median":40.395099,"eighty":45.667046,"marketCap":4862056020},{"date":"2022-04-14","current":40.742313,"twenty":32.769192,"median":40.404479,"eighty":45.667046,"marketCap":4981684815},{"date":"2022-04-22","current":42.01187,"twenty":32.769192,"median":40.455317,"eighty":45.667046,"marketCap":5136917418},{"date":"2022-04-29","current":39.554287,"twenty":32.79826,"median":40.479695,"eighty":45.667046,"marketCap":4836421278},{"date":"2022-05-06","current":39.499614,"twenty":32.904642,"median":40.479695,"eighty":45.667046,"marketCap":5066773466},{"date":"2022-05-13","current":39.967203,"twenty":32.996397,"median":40.479695,"eighty":45.667046,"marketCap":5126753027},{"date":"2022-05-20","current":39.90291,"twenty":33.05702,"median":40.479695,"eighty":45.667046,"marketCap":5118505838},{"date":"2022-05-27","current":40.353768,"twenty":33.088236,"median":40.495181,"eighty":45.667046,"marketCap":5176339242},{"date":"2022-06-03","current":40.599257,"twenty":33.156377,"median":40.53176,"eighty":45.667046,"marketCap":5207829139},{"date":"2022-06-10","current":41.119461,"twenty":33.227354,"median":40.613635,"eighty":45.667046,"marketCap":5274557730},{"date":"2022-06-17","current":40.213488,"twenty":33.270165,"median":40.613635,"eighty":45.667046,"marketCap":5158345016},{"date":"2022-06-24","current":43.32302,"twenty":33.260026,"median":40.659236,"eighty":45.668114,"marketCap":5557217043},{"date":"2022-07-01","current":42.978166,"twenty":33.330747,"median":40.684242,"eighty":45.668114,"marketCap":5512981235},{"date":"2022-07-08","current":42.872956,"twenty":33.466784,"median":40.715658,"eighty":45.668114,"marketCap":5499485565},{"date":"2022-07-15","current":43.708789,"twenty":33.59929,"median":40.742313,"eighty":45.668114,"marketCap":5606701167},{"date":"2022-07-22","current":44.556311,"twenty":33.59929,"median":40.778643,"eighty":45.668114,"marketCap":5715416287},{"date":"2022-07-29","current":46.520226,"twenty":33.675236,"median":40.820493,"eighty":45.678143,"marketCap":5967335462},{"date":"2022-08-05","current":43.100932,"twenty":33.675236,"median":40.862996,"eighty":45.68777,"marketCap":6116022220},{"date":"2022-08-12","current":44.318758,"twenty":33.675236,"median":40.912721,"eighty":45.68777,"marketCap":6288831702},{"date":"2022-08-19","current":44.509569,"twenty":33.675236,"median":40.969109,"eighty":45.68777,"marketCap":6315907842},{"date":"2022-08-26","current":43.241234,"twenty":33.675236,"median":41.010201,"eighty":45.68777,"marketCap":6135931147},{"date":"2022-09-02","current":41.585665,"twenty":33.675236,"median":41.060268,"eighty":45.68777,"marketCap":5901005814},{"date":"2022-09-09","current":41.956063,"twenty":33.675236,"median":41.092655,"eighty":45.68777,"marketCap":5953565380},{"date":"2022-09-16","current":40.805583,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5790312183},{"date":"2022-09-23","current":39.935707,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5666876838},{"date":"2022-09-30","current":37.927001,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5381841428},{"date":"2022-10-07","current":36.428553,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5169211706},{"date":"2022-10-14","current":35.631626,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5056127734},{"date":"2022-10-21","current":36.636203,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5198677248},{"date":"2022-10-28","current":38.359137,"twenty":33.675236,"median":41.109476,"eighty":45.68777,"marketCap":5443161610},{"date":"2022-11-04","current":41.724424,"twenty":33.675236,"median":41.119461,"eighty":45.68777,"marketCap":6035896875},{"date":"2022-11-11","current":42.347632,"twenty":33.675236,"median":41.160749,"eighty":45.68777,"marketCap":6126050848},{"date":"2022-11-18","current":42.756995,"twenty":33.675236,"median":41.197005,"eighty":45.68777,"marketCap":6185269635},{"date":"2022-11-25","current":43.056379,"twenty":33.675236,"median":41.218321,"eighty":45.68777,"marketCap":6228578896},{"date":"2022-12-02","current":43.196907,"twenty":33.675236,"median":41.257018,"eighty":45.68777,"marketCap":6248907733},{"date":"2022-12-09","current":43.795676,"twenty":33.675236,"median":41.35326,"eighty":45.68777,"marketCap":6335526256},{"date":"2022-12-16","current":43.172467,"twenty":33.675236,"median":41.423201,"eighty":45.68777,"marketCap":6245372283},{"date":"2022-12-23","current":43.685698,"twenty":33.675236,"median":41.463369,"eighty":45.68777,"marketCap":6319616732},{"date":"2022-12-30","current":43.337434,"twenty":33.675236,"median":41.483593,"eighty":45.68777,"marketCap":6269236570},{"date":"2023-01-06","current":43.245786,"twenty":34.167053,"median":41.539601,"eighty":45.68777,"marketCap":6255978633},{"date":"2023-01-13","current":45.714181,"twenty":34.992765,"median":41.587683,"eighty":45.704396,"marketCap":6613059075},{"date":"2023-01-20","current":45.402576,"twenty":35.880519,"median":41.605991,"eighty":45.714503,"marketCap":6567982088},{"date":"2023-01-27","current":45.378137,"twenty":36.169649,"median":41.646285,"eighty":45.714503,"marketCap":6564446638},{"date":"2023-02-03","current":45.255939,"twenty":36.592515,"median":41.674422,"eighty":45.714503,"marketCap":6546769389},{"date":"2023-02-10","current":44.406665,"twenty":36.713651,"median":41.711398,"eighty":45.714503,"marketCap":6423912504},{"date":"2023-02-17","current":44.157808,"twenty":36.89773,"median":41.739833,"eighty":45.714503,"marketCap":6731283715},{"date":"2023-02-24","current":42.410386,"twenty":36.963658,"median":41.754028,"eighty":45.714503,"marketCap":6464912060},{"date":"2023-03-03","current":41.690165,"twenty":37.214665,"median":41.783816,"eighty":45.714503,"marketCap":6355123742},{"date":"2023-03-10","current":39.423241,"twenty":37.286636,"median":41.783816,"eighty":45.714503,"marketCap":6009560514},{"date":"2023-03-17","current":40.355986,"twenty":37.342014,"median":41.783816,"eighty":45.714503,"marketCap":6151745384},{"date":"2023-03-24","current":39.606247,"twenty":37.466803,"median":41.783816,"eighty":45.714503,"marketCap":6037457546},{"date":"2023-03-31","current":40.621801,"twenty":37.536428,"median":41.78137,"eighty":45.714342,"marketCap":6192265465},{"date":"2023-04-06","current":39.692254,"twenty":37.577737,"median":41.783816,"eighty":45.714503,"marketCap":6050568092},{"date":"2023-04-14","current":39.289647,"twenty":37.687654,"median":41.784219,"eighty":45.714663,"marketCap":5989195981},{"date":"2023-04-21","current":39.792905,"twenty":37.872566,"median":41.784621,"eighty":45.714824,"marketCap":6065911119},{"date":"2023-04-28","current":40.118543,"twenty":37.943837,"median":41.797292,"eighty":45.714985,"marketCap":6115550327},{"date":"2023-05-05","current":39.964605,"twenty":38.110019,"median":41.797292,"eighty":45.714985,"marketCap":6092084520},{"date":"2023-05-12","current":39.104119,"twenty":38.249787,"median":41.797292,"eighty":45.714985,"marketCap":6176026400},{"date":"2023-05-19","current":38.898029,"twenty":38.342909,"median":41.797292,"eighty":45.714985,"marketCap":6143476946},{"date":"2023-05-26","current":37.796919,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5969569863},{"date":"2023-06-02","current":37.832249,"twenty":38.456408,"median":41.797292,"eighty":45.714985,"marketCap":5975149770},{"date":"2023-06-09","current":38.668386,"twenty":38.476762,"median":41.797292,"eighty":45.714985,"marketCap":6107207554},{"date":"2023-06-16","current":38.786152,"twenty":38.533217,"median":41.797292,"eighty":45.714985,"marketCap":6125807242},{"date":"2023-06-23","current":38.509402,"twenty":38.553397,"median":41.809962,"eighty":45.718688,"marketCap":6082097976},{"date":"2023-06-30","current":38.55062,"twenty":38.5799,"median":41.81327,"eighty":45.72239,"marketCap":6088607866},{"date":"2023-07-07","current":38.662498,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6106277570},{"date":"2023-07-14","current":38.603615,"twenty":38.628346,"median":41.81327,"eighty":45.72239,"marketCap":6096977726},{"date":"2023-07-21","current":39.357316,"twenty":38.659115,"median":41.81327,"eighty":45.72239,"marketCap":6216015729},{"date":"2023-07-28","current":39.404422,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6223455604},{"date":"2023-08-04","current":38.053978,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6196443469},{"date":"2023-08-11","current":37.511193,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":6108060089},{"date":"2023-08-18","current":36.166029,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5889023018},{"date":"2023-08-25","current":36.531819,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5948585730},{"date":"2023-09-01","current":36.472821,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5938978841},{"date":"2023-09-08","current":35.75304,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5821774794},{"date":"2023-09-15","current":35.446248,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5771818971},{"date":"2023-09-22","current":33.711695,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5489376431},{"date":"2023-09-29","current":32.567126,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5303002783},{"date":"2023-10-06","current":32.649724,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5316452427},{"date":"2023-10-13","current":31.806046,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5179073913},{"date":"2023-10-20","current":32.41963,"twenty":38.699097,"median":41.81327,"eighty":45.72239,"marketCap":5278985560},{"date":"2023-10-27","current":33.181375,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5472604212},{"date":"2023-11-03","current":35.377246,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5834769220},{"date":"2023-11-10","current":34.598655,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5706356142},{"date":"2023-11-17","current":35.425908,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5842795038},{"date":"2023-11-24","current":35.170433,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5800659496},{"date":"2023-12-01","current":36.015934,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":5940108073},{"date":"2023-12-08","current":36.873602,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6081563104},{"date":"2023-12-15","current":37.7556,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6227031044},{"date":"2023-12-22","current":37.968496,"twenty":38.730653,"median":41.843819,"eighty":45.729795,"marketCap":6262143995},{"date":"2023-12-29","current":38.607184,"twenty":38.744189,"median":41.871061,"eighty":45.733498,"marketCap":6367482847},{"date":"2024-01-05","current":38.296964,"twenty":38.756995,"median":41.871582,"eighty":45.73451,"marketCap":6316318262},{"date":"2024-01-12","current":38.090151,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":6282208538},{"date":"2024-01-19","current":36.989174,"twenty":38.764196,"median":41.872103,"eighty":45.735522,"marketCap":6100624420},{"date":"2024-01-26","current":36.295741,"twenty":38.758791,"median":41.871582,"eighty":45.73451,"marketCap":5986256523},{"date":"2024-02-02","current":37.232484,"twenty":38.697827,"median":41.871582,"eighty":45.73451,"marketCap":6140753507},{"date":"2024-02-09","current":35.261674,"twenty":38.661168,"median":41.871582,"eighty":45.73451,"marketCap":5815707904},{"date":"2024-02-16","current":33.847315,"twenty":38.629468,"median":41.871582,"eighty":45.73451,"marketCap":5752655855},{"date":"2024-02-23","current":33.670228,"twenty":38.597685,"median":41.871582,"eighty":45.73451,"marketCap":5722558249},{"date":"2024-03-01","current":32.436519,"twenty":38.556509,"median":41.871061,"eighty":45.733498,"marketCap":5512878257},{"date":"2024-03-08","current":33.758772,"twenty":38.535146,"median":41.871061,"eighty":45.733498,"marketCap":5737607052},{"date":"2024-03-15","current":32.6018,"twenty":38.489062,"median":41.871061,"eighty":45.733498,"marketCap":5540969356},{"date":"2024-03-22","current":33.262927,"twenty":38.456408,"median":41.871061,"eighty":45.733498,"marketCap":5653333754},{"date":"2024-03-28","current":33.457723,"twenty":38.385748,"median":41.784621,"eighty":45.733498,"marketCap":5686441121},{"date":"2024-04-05","current":33.192092,"twenty":38.338315,"median":41.766476,"eighty":45.73451,"marketCap":5641294711},{"date":"2024-04-12","current":33.499043,"twenty":38.271415,"median":41.746116,"eighty":45.73451,"marketCap":5693463896},{"date":"2024-04-19","current":32.99201,"twenty":38.226469,"median":41.73308,"eighty":45.73451,"marketCap":5607289064},{"date":"2024-04-26","current":33.647761,"twenty":38.150217,"median":41.720309,"eighty":45.733498,"marketCap":5827926731},{"date":"2024-05-03","current":33.618779,"twenty":38.090151,"median":41.711398,"eighty":45.733498,"marketCap":5822906984},{"date":"2024-05-10","current":34.482434,"twenty":38.029323,"median":41.69585,"eighty":45.733498,"marketCap":5972495456},{"date":"2024-05-17","current":34.986715,"twenty":37.950247,"median":41.66791,"eighty":45.733498,"marketCap":6059839061},{"date":"2024-05-24","current":34.198413,"twenty":37.871294,"median":41.619337,"eighty":45.733498,"marketCap":5923301932},{"date":"2024-05-31","current":34.928752,"twenty":37.820473,"median":41.602226,"eighty":45.733498,"marketCap":6049799566},{"date":"2024-06-07","current":35.908334,"twenty":37.7418,"median":41.585665,"eighty":45.733498,"marketCap":6219467028},{"date":"2024-06-14","current":35.311311,"twenty":37.642264,"median":41.478607,"eighty":45.73451,"marketCap":6116060232},{"date":"2024-06-21","current":35.485201,"twenty":37.563829,"median":41.447441,"eighty":45.735522,"marketCap":6146178716},{"date":"2024-06-28","current":35.734443,"twenty":37.537078,"median":41.447441,"eighty":45.738558,"marketCap":6189348544},{"date":"2024-07-05","current":35.879352,"twenty":37.482188,"median":41.447441,"eighty":45.738558,"marketCap":6214447281},{"date":"2024-07-12","current":36.957471,"twenty":37.418215,"median":41.439295,"eighty":45.738558,"marketCap":6401181884},{"date":"2024-07-15","current":37.189325,"twenty":37.412399,"median":41.439295,"eighty":45.738558,"marketCap":6441339863},{"date":"2024-08-02","current":37.993919,"twenty":37.339153,"median":41.40142,"eighty":45.707657,"marketCap":7107142493},{"date":"2024-08-09","current":38.417922,"twenty":37.339153,"median":41.351038,"eighty":45.669183,"marketCap":7186456557},{"date":"2024-08-16","current":38.455492,"twenty":37.339153,"median":41.248609,"eighty":45.587895,"marketCap":7193484385},{"date":"2024-08-23","current":38.879496,"twenty":37.339153,"median":41.197005,"eighty":45.51208,"marketCap":7272798449},{"date":"2024-08-30","current":39.104915,"twenty":37.339153,"median":41.152223,"eighty":45.432939,"marketCap":7314965420},{"date":"2024-09-06","current":40.19981,"twenty":37.339153,"median":41.109476,"eighty":45.406991,"marketCap":7519776420},{"date":"2024-09-13","current":40.725789,"twenty":37.339153,"median":41.060268,"eighty":45.379705,"marketCap":7618166018},{"date":"2024-09-20","current":39.786541,"twenty":37.339153,"median":41.020981,"eighty":45.296882,"marketCap":7442470307},{"date":"2024-09-27","current":39.931453,"twenty":37.339153,"median":40.992653,"eighty":45.271719,"marketCap":7469577645},{"date":"2024-10-04","current":40.355457,"twenty":37.339153,"median":40.937316,"eighty":45.211095,"marketCap":7548891709},{"date":"2024-10-11","current":39.3196,"twenty":37.339153,"median":40.894276,"eighty":45.159517,"marketCap":7355124439},{"date":"2024-10-18","current":40.731156,"twenty":37.339153,"median":40.838938,"eighty":45.089028,"marketCap":7619169993},{"date":"2024-10-25","current":42.532506,"twenty":37.339153,"median":40.820493,"eighty":45.046981,"marketCap":8077475775},{"date":"2024-10-31","current":40.816625,"twenty":37.339153,"median":40.816625,"eighty":44.988744,"marketCap":7751607762},{"date":"2024-11-08","current":40.076878,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7611120201},{"date":"2024-11-15","current":41.115788,"twenty":37.338438,"median":40.773001,"eighty":44.942004,"marketCap":7808422584},{"date":"2024-11-22","current":41.948003,"twenty":37.338438,"median":40.773001,"eighty":44.914929,"marketCap":7966471090},{"date":"2024-11-29","current":41.773945,"twenty":37.338438,"median":40.773001,"eighty":44.914324,"marketCap":7933415193},{"date":"2024-12-06","current":40.849261,"twenty":37.338438,"median":40.770318,"eighty":44.892115,"marketCap":7757805742},{"date":"2024-12-13","current":40.055121,"twenty":37.338438,"median":40.736734,"eighty":44.892115,"marketCap":7606988214},{"date":"2024-12-20","current":37.770608,"twenty":37.338438,"median":40.680888,"eighty":44.892115,"marketCap":7173129570},{"date":"2024-12-27","current":38.515795,"twenty":37.338438,"median":40.640959,"eighty":44.892115,"marketCap":7314650128},{"date":"2025-01-03","current":37.933788,"twenty":37.338438,"median":40.614232,"eighty":44.892115,"marketCap":7204119473},{"date":"2025-01-10","current":37.906591,"twenty":37.337724,"median":40.580698,"eighty":44.89414,"marketCap":7198954490},{"date":"2025-01-17","current":39.244663,"twenty":37.333873,"median":40.538993,"eighty":44.89414,"marketCap":7453071695},{"date":"2025-01-24","current":38.87479,"twenty":37.333873,"median":40.501145,"eighty":44.89414,"marketCap":7382827915},{"date":"2025-01-31","current":39.761398,"twenty":37.333873,"median":40.465332,"eighty":44.84311,"marketCap":7551206388},{"date":"2025-02-07","current":39.74508,"twenty":37.333873,"median":40.424995,"eighty":44.718497,"marketCap":7548107398},{"date":"2025-02-14","current":40.634976,"twenty":37.333873,"median":40.403761,"eighty":44.67404,"marketCap":7688015540},{"date":"2025-02-21","current":40.363435,"twenty":37.333873,"median":40.374953,"eighty":44.653159,"marketCap":7636640801},{"date":"2025-02-28","current":41.687197,"twenty":37.333873,"median":40.374953,"eighty":44.559412,"marketCap":7887092651},{"date":"2025-03-07","current":42.394335,"twenty":37.33306,"median":40.37194,"eighty":44.562299,"marketCap":8020881032},{"date":"2025-03-14","current":42.767704,"twenty":37.33306,"median":40.383179,"eighty":44.562299,"marketCap":8091521298},{"date":"2025-03-21","current":43.141073,"twenty":37.417052,"median":40.40791,"eighty":44.562299,"marketCap":8162161563},{"date":"2025-03-28","current":42.993988,"twenty":37.479862,"median":40.452151,"eighty":44.562299,"marketCap":8134333580},{"date":"2025-04-04","current":43.440899,"twenty":37.536428,"median":40.487288,"eighty":44.562299,"marketCap":8218887836},{"date":"2025-04-11","current":41.268572,"twenty":37.537078,"median":40.501145,"eighty":44.559412,"marketCap":7807889929},{"date":"2025-04-17","current":44.145605,"twenty":37.540692,"median":40.519212,"eighty":44.559412,"marketCap":8352216066},{"date":"2025-04-25","current":43.782817,"twenty":37.571542,"median":40.572736,"eighty":44.653759,"marketCap":8377141546},{"date":"2025-05-02","current":45.953462,"twenty":37.571542,"median":40.583839,"eighty":44.677947,"marketCap":8792459672},{"date":"2025-05-09","current":43.031008,"twenty":37.571542,"median":40.598117,"eighty":44.677947,"marketCap":8233294969},{"date":"2025-05-16","current":42.422675,"twenty":37.571542,"median":40.624906,"eighty":44.677947,"marketCap":8116900028},{"date":"2025-05-23","current":42.755537,"twenty":37.571542,"median":40.666871,"eighty":44.677947,"marketCap":8180587826}],"updateTime":1748366147991}}}